# OnCo record sapu-003 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/sapu-003/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "sapu-003" ;
  schema:name "Sapu003 (SAPU-003, everolimus Deciparticle)"@en ;
  schema:alternateName "SAPU-003"@en, "Sapu003"@en, "Sapu 003"@en, "Sapu003/Everolimus for Injection"@en ;
  schema:description "Sapu003 (SAPU-003, everolimus Deciparticle) is an experimental sub-20 nm nanoparticle intravenous formulation of everolimus from Sapu Nano, in phase 1 trials for HR-positive HER2-negative metastatic breast cancer, renal cell carcinoma and neuroendocrine tumours and other cancers."@en ;
  schema:url <https://onco.cc/drugs/sapu-003/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://sapunano.com/sapu003/>, <https://sapunano.com/sapu003/>, <https://sapunano.com/pipeline/>, <https://sapunano.com/news/>, <https://clinicaltrials.gov/search?intr=SAPU-003> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Sub-20 nm nanoparticle (Deciparticle) intravenous formulation of everolimus" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/neuroendocrine/>, <https://onco.cc/cancers/hcc/> ;
  onco:targets <https://onco.cc/targets/mtor/> ;
  onco:companies <https://onco.cc/companies/sapu-nano/> ;
  onco:trials <https://onco.cc/trials/nct07369505/> .